Stock KDEV KAROLINSKA DEVELOPMENT AB
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Karolinska Development AB

Equities

KDEV

SE0002190926

Market Closed - Nasdaq Stockholm
Other stock markets
 11:17:16 2024-05-03 am EDT 		5-day change 1st Jan Change
1.58 SEK 0.00% Intraday chart for Karolinska Development AB +0.64% -6.95%
Apr. 26 Karolinska Development AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 16 Karolinska Development AB Announces That Björn Cochlovius Has Declined Re-Election CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Interim Report - January-March 2024
GL
Notice of Annual General Meeting in Karolinska Development AB (publ)
GL
Karolinska Development : portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC
PU
Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC
GL
Karolinska Development Annual Report 2023 published
GL
Karolinska Development Annual Report 2023 published
AQ
Karolinska Development : portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million
PU
Karolinska Development’s portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million
GL
Karolinska Development : portfolio company Biosergen publishes prospectus due to rights issue of units
PU
Karolinska Development’s portfolio company Biosergen publishes prospectus due to rights issue of units
GL
Karolinska Development : portfolio company Umecrine Cognition presents preclinical Parkinson's data on golexanolone at AD/PD
PU
Karolinska Development’s portfolio company Umecrine Cognition presents preclinical Parkinson’s data on golexanolone at AD/PD
GL
Year-end Report - January-December 2023
GL
Karolinska Development’s portfolio company AnaCardio secures SEK 50 million as part of its Series A investment round
GL
Karolinska Development's portfolio company OssDsign reports exceptional clinical data for its nanosynthetic bone graft product
GL
Karolinska Development's portfolio company OssDsign expects fourth-quarter revenues to exceed market estimates
GL
Karolinska Development’s portfolio company PharmNovo´s drug candidate PN6047 in a NIDA funded collaboration
GL
Karolinska Development’s portfolio company PharmNovo´s drug candidate PN6047 in a NIDA funded collaboration
AQ
Karolinska Development’s portfolio company Umecrine Cognition presents positive effects of golexanolone in a preclinical model of cholestasis
GL
Karolinska Development’s portfolio company Umecrine Cognition raises additional funding for the clinical development of golexanolone
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KDEV Stock
  4. News Karolinska Development AB
  5. Press Releases